Funding for this research was provided by:
Milgrom Family Foundation (034.4768)
Ministry of Defense (69_18)
Received: 9 November 2018
Accepted: 8 May 2019
First Online: 26 June 2019
Ethics approval and consent to participate
: The study was approved by the Hadassah Medical Center and IDF institutional review board (IRB) committees. Approval number: 1490–2015.All participants provided consent by signing an electronic form and replying “approve” to a text-message they received after completing the form. This was approved by the IRB committees under the condition that participants received the option to have a conversation with one of the researchers prior to completing enrollment. This process is mentioned in article (f) in the section describing the enrollment process.
: Not applicable.
: YBZ has received fees for lectures and conference attendance from Pfizer Israel Ltd. (2012–2015; 2017–2018), and fees for lectures from Novartis NCH in Israel (2012–2015). HL received fees for lectures from Pfizer Israel Ltd. (2017). Both companies distribute smoking cessation pharmacotherapy in Israel. All other authors declare no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.